ImmunoCellular治療公司 (IMUC)

0.1979 0.0000 (0.00%) 市場開市。 截至 09:43AM EDT。

ImmunoCellular治療公司

136 Summit Avenue
Montvale, NJ 07645
United States
201 351 0605
https://www.eompharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 3

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Irach B. Taraporewala B.S., M.S., Ph.D.	CEO, President & Director	265.65k	無	1956
Mr. Wayne I. Danson CPA	CFO & Treasurer	150k	無	1954
Mr. Eli Goldberger	Founder, Chairman & COO	無	無	1990
Dr. Shalom Z. Hirschman M.D.	Co-Founder, Chief Scientific Officer & Medical Director	無	無	1936

截止 2021年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

公司管治

截至 無 止，ImmunoCellular治療公司 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。